Table 3 Data from 46 adjuvant radiotherapies from 43 patients

Age at adjuvant radiotherapy (years)

 Mean/SD/median/range

64.8/5.81/65.3/75 - 54

Time from salvage lymph node dissection to adjuvant RT (months)

 Mean/SD/median/range

2.75/1.72/2.20/8.4 - 0.8

Region for adjuvant RT n (%)

 Pelvic right only

2/46 (4.3%)

 Pelvic left only

5/46 (10.9%)

 Pelvic only (left/right/bilateral)

26/46 (57%)

 Retroperitoneal only

5/46 (11%)

 Pelvic and retroperitoneal

14/46 (30%)

 Retroclavicular and retroperitoneal

1/46 (2%)

 Cases with dose escalation on involved region n (%)

11/46 (24.0%)

Method of adjuvant radiotherapy

 3D-conformal radiotherapy n (%)

29/46 (63%)

 IMRT n (%)

17/46 (37.0%)

 Concurrent radiation of prostatic fossa n (%)

12/46 (26.1%)

Total dose for radiation of prostatic fossa (Gy)

 Mean/SD/median/range

69.18/2.38/70.20/45.0 – 72.2

Duration of adjuvant radiotherapy (months)

 Mean/SD/median/range

1.39/0.35/1.37/2.4 – 1.0

 Dose per fraction (Gy)

1.8, 5x1.8/week

Total dose for pelvic or retroperitoneal RT (Gy)

 Mean/SD/median/range

49.55/4.16/50.40/45.0 – 59.4

 Number of cases with concurrent AHT at radiotherapy n (%)

2/46 (4.3%)

 Patients with concurrent AHT at latest follow up

27/43 (62.8%)

Comorbidities at latest follow¹ up n (%)

 Cardiovascular disease n (%)

10/38 (26.4%)

 Diabetes mellitus n (%)

3/38 (7.9%)

 Concurrent malignant disease n (%)

3/38 (7.9%)

 Chronic disease/chronic pain n (%)

6/38 (15.9%)